Day: October 17, 2021

Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS

Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS

In the Phase 3 VALOR study, the primary endpoint as measured by the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) did not reach statistical significance; however, signs of reduced disease progression across multiple secondary and exploratory endpoints were observed The totality of evidence from VALOR and its ongoing open-label extension showed that participants who started tofersen earlier experienced better outcomes, further suggesting a positive clinical effect Topline data being presented today at the American Neurological Association 2021 Annual Meeting Given the high unmet medical need, Biogen will expand its ongoing early access program (EAP) to the broader SOD1-ALS population A Media Snippet accompanying this announcement is available by clicking on the image or link below: CAMBRIDGE, Mass., Oct. 17,...

Continue reading

68 MW wind power agreement has been terminated by Commerz Real

68 MW wind power agreement has been terminated by Commerz Real

Hässleholm, Sweden, October 17th, 2021 On September 29th, 2020, Eolus announced the sale of three wind farms in Sweden with an installed capacity of 68 MW. Eolus has been notified that the investor Commerz Real has terminated the share purchase agreement due to conditions for the transaction not being fulfilled. As a consequence of the terminated agreement Eolus’ order backlog will decrease with the amount of EUR 82.5 million and signed contracts for future asset management services will decrease by 68 MW. No revenues from the agreement have been recognized in Eolus’ financial reports. Eolus will pay a termination fee of 200,000 EUR to the investor Commerz Real. Conditions not fulfilled relates to sufficient permits not being granted by the authorities before the long-stop date in the agreement between Eolus and Commerz Real. Eolus will...

Continue reading

Core One Labs Applauds the City of Seattle in Their Efforts to Decriminalize Psylocibin and Other Natural Occuring Entheogenic Drugs

Core One Labs Applauds the City of Seattle in Their Efforts to Decriminalize Psylocibin and Other Natural Occuring Entheogenic Drugs

VANCOUVER, British Columbia, Oct. 16, 2021 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (FWB: LD6, WKN: A3CSSU) (the “Company”) a research and technology company focused in life sciences and on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy, congratulates Seattle’s city council in their unanimous vote to decriminalize the use, possession and cultivation of naturally occurring entheogenic drugs, including psilocybin for “religious, spiritual, healing or personal growth practices.” On Monday, October 4, 2021, the City of Seattle officially became the largest city in the United States to decriminalize non-commercial use around a number of psychedelic substances that originate from “living, fresh, dried or processed plant or fungal material, including...

Continue reading